Rhythm Pharmaceuticals (RYTM) to Release Quarterly Earnings on Wednesday

Rhythm Pharmaceuticals (NASDAQ:RYTM) is expected to be posting its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Rhythm Pharmaceuticals to post earnings of ($0.80) per share for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 12:30 PM ET.

Rhythm Pharmaceuticals Stock Up 4.5%

RYTM stock opened at $102.53 on Wednesday. The stock has a market capitalization of $6.84 billion, a PE ratio of -33.07 and a beta of 2.00. Rhythm Pharmaceuticals has a 52 week low of $45.90 and a 52 week high of $122.20. The firm has a 50 day moving average of $106.05 and a 200 day moving average of $103.25.

Insider Activity

In related news, insider Pamela J. Cramer sold 3,350 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $111.00, for a total transaction of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares in the company, valued at approximately $2,310,354. This trade represents a 13.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Hunter C. Smith sold 3,381 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The stock was sold at an average price of $106.06, for a total value of $358,588.86. Following the completion of the sale, the chief financial officer owned 125,537 shares in the company, valued at approximately $13,314,454.22. This represents a 2.62% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 17,049 shares of company stock valued at $1,783,165. Insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RYTM. Smartleaf Asset Management LLC boosted its stake in shares of Rhythm Pharmaceuticals by 39.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock worth $43,000 after acquiring an additional 113 shares in the last quarter. Osaic Holdings Inc. boosted its position in Rhythm Pharmaceuticals by 65.9% during the second quarter. Osaic Holdings Inc. now owns 979 shares of the company’s stock worth $62,000 after purchasing an additional 389 shares in the last quarter. State of Wyoming acquired a new stake in Rhythm Pharmaceuticals in the second quarter valued at approximately $67,000. Persistent Asset Partners Ltd purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter valued at approximately $155,000. Finally, Abel Hall LLC acquired a new position in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $229,000.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on RYTM shares. Zacks Research downgraded shares of Rhythm Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. The Goldman Sachs Group lifted their price target on Rhythm Pharmaceuticals from $141.00 to $157.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Morgan Stanley reiterated an “overweight” rating and set a $150.00 price target on shares of Rhythm Pharmaceuticals in a research note on Thursday, December 11th. Canaccord Genuity Group raised their price objective on Rhythm Pharmaceuticals from $114.00 to $141.00 and gave the stock a “buy” rating in a research note on Friday, December 12th. Finally, HC Wainwright lifted their target price on Rhythm Pharmaceuticals from $123.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, January 20th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Rhythm Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $130.46.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.